Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon.
Department of Medical Oncology, Hospital Clinico San Carlos, IdISSC, Calle Profesor Martín Lagos, Madrid, Spain.
JAMA Oncol. 2024 Jan 1;10(1):71-78. doi: 10.1001/jamaoncol.2023.4837.
Stage at diagnosis is a key prognostic factor for cancer survival.
To assess the global distribution of breast cancer stage by country, age group, calendar period, and socioeconomic status using population-based data.
A systematic search of MEDLINE and Web of Science databases and registry websites and gray literature was conducted for articles or reports published between January 1, 2000, and June 20, 2022.
Reports on stage at diagnosis for individuals with primary breast cancer (C50) from a population-based cancer registry were included.
Study characteristics and results of eligible studies were independently extracted by 2 pairs of reviewers (J.D.B.F., A.D.A., A.M., R.S., and F.G.). Stage-specific proportions were extracted and cancer registry data quality and risk of bias were assessed. National pooled estimates were calculated for subnational or annual data sets using a hierarchical rule of the most relevant and high-quality data to avoid duplicates.
The proportion of women with breast cancer by (TNM Classification of Malignant Tumors or the Surveillance, Epidemiology, and End Results Program [SEER]) stage group.
Data were available for 2.4 million women with breast cancer from 81 countries. Globally, the proportion of cases with distant metastatic breast cancer at diagnosis was high in sub-Saharan Africa, ranging from 5.6% to 30.6% and low in North America ranging from 0.0% to 6.0%. The proportion of patients diagnosed with distant metastatic disease decreased over the past 2 decades from around 3.8% to 35.8% (early 2000s) to 3.2% to 11.6% (2015 onwards), yet stabilization or slight increases were also observed. Older age and lower socioeconomic status had the largest proportion of cases diagnosed with distant metastatic stage ranging from 2.0% to 15.7% among the younger to 4.1% to 33.9% among the oldest age group, and from 1.7% to 8.3% in the least disadvantaged groups to 2.8% to 11.4% in the most disadvantaged groups.
Effective policy and interventions have resulted in decreased proportions of women diagnosed with metastatic breast cancer at diagnosis in high-income countries, yet inequality persists, which needs to be addressed through increased awareness of breast cancer symptoms and early detection. Improving global coverage and quality of population-based cancer registries, including the collection of standardized stage data, is key to monitoring progress.
诊断时的分期是癌症生存的一个关键预后因素。
使用基于人群的数据评估全球各国、年龄组、时间区间和社会经济地位的乳腺癌分期分布。
对 MEDLINE 和 Web of Science 数据库以及登记处网站和灰色文献进行了系统搜索,以获取 2000 年 1 月 1 日至 2022 年 6 月 20 日期间发表的关于原发性乳腺癌(C50)患者诊断时分期的文章或报告。
纳入了来自人群癌症登记处的关于原发性乳腺癌(C50)患者诊断时分期的报告。
由 2 对评审员(J.D.B.F.、A.D.A.、A.M.、R.S.和 F.G.)独立提取研究特征和合格研究的结果。提取了特定分期的比例,并评估了癌症登记处的数据质量和偏倚风险。使用最相关和高质量数据的分层规则,对国家级或年度数据集进行了国家汇总估计,以避免重复。
(TNM 肿瘤分类或监测、流行病学和最终结果计划 [SEER])分期组中乳腺癌女性的比例。
来自 81 个国家的 240 万名乳腺癌患者的数据可用。在撒哈拉以南非洲,诊断时远处转移性乳腺癌的病例比例较高,范围为 5.6%至 30.6%,而在北美,比例较低,范围为 0.0%至 6.0%。过去 20 年来,远处转移性疾病的诊断比例从 3.8%至 35.8%(2000 年代早期)降至 3.2%至 11.6%(2015 年以后)有所下降,但也观察到稳定或略有增加。年龄较大和社会经济地位较低的患者中,远处转移性分期的病例比例最大,从年轻组的 2.0%至 15.7%到老年组的 4.1%至 33.9%不等,从社会经济地位最低组的 1.7%至 8.3%到社会经济地位最高组的 2.8%至 11.4%不等。
有效的政策和干预措施已导致高收入国家诊断为转移性乳腺癌的女性比例下降,但不平等仍然存在,这需要通过提高对乳腺癌症状的认识和早期发现来解决。提高全球人群癌症登记处的覆盖率和质量,包括标准化分期数据的收集,是监测进展的关键。